FINE FOODS & PHARMACEUTICALS (FF.MI) Stock Fundamental Analysis
Europe - Euronext Milan - BIT:FF - IT0005215329 - Common Stock
9.62 EUR
+0.08 (+0.84%)
Overall FF gets a fundamental rating of 6 out of 10. We evaluated FF against 22 industry peers in the Life Sciences Tools & Services industry. Both the profitability and the financial health of FF get a neutral evaluation. Nothing too spectacular is happening here. A decent growth rate in combination with a cheap valuation! Better keep an eye on FF. These ratings could make FF a good candidate for value investing.
1. Profitability
1.1 Basic Checks
In the past year FF was profitable.
In the past year FF had a positive cash flow from operations.
In multiple years FF reported negative net income over the last 5 years.
Of the past 5 years FF 4 years had a positive operating cash flow.
1.2 Ratios
FF has a better Return On Assets (6.89%) than 81.82% of its industry peers.
FF's Return On Equity of 13.58% is amongst the best of the industry. FF outperforms 81.82% of its industry peers.
FF's Return On Invested Capital of 9.84% is amongst the best of the industry. FF outperforms 81.82% of its industry peers.
The Average Return On Invested Capital over the past 3 years for FF is significantly below the industry average of 9.34%.
The 3 year average ROIC (3.16%) for FF is below the current ROIC(9.84%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.89% | ||
| ROE | 13.58% | ||
| ROIC | 9.84% |
ROA(3y)-0.42%
ROA(5y)0.94%
ROE(3y)-1.24%
ROE(5y)0.96%
ROIC(3y)3.16%
ROIC(5y)3.16%
1.3 Margins
FF's Profit Margin of 5.07% is on the low side compared to the rest of the industry. FF is outperformed by 68.18% of its industry peers.
FF has a worse Operating Margin (7.85%) than 77.27% of its industry peers.
In the last couple of years the Operating Margin of FF has grown nicely.
The Gross Margin of FF (34.77%) is comparable to the rest of the industry.
In the last couple of years the Gross Margin of FF has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.85% | ||
| PM (TTM) | 5.07% | ||
| GM | 34.77% |
OM growth 3Y24.97%
OM growth 5Y2.12%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.32%
GM growth 5Y2.27%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so FF is still creating some value.
Compared to 1 year ago, FF has about the same amount of shares outstanding.
Compared to 5 years ago, FF has more shares outstanding
FF has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 3.06 indicates that FF is not in any danger for bankruptcy at the moment.
With a Altman-Z score value of 3.06, FF perfoms like the industry average, outperforming 54.55% of the companies in the same industry.
A Debt/Equity ratio of 0.44 indicates that FF is not too dependend on debt financing.
FF has a Debt to Equity ratio of 0.44. This is in the better half of the industry: FF outperforms 77.27% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.44 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.06 |
ROIC/WACC1.09
WACC9%
2.3 Liquidity
A Current Ratio of 1.67 indicates that FF should not have too much problems paying its short term obligations.
FF's Current ratio of 1.67 is amongst the best of the industry. FF outperforms 86.36% of its industry peers.
FF has a Quick Ratio of 1.07. This is a normal value and indicates that FF is financially healthy and should not expect problems in meeting its short term obligations.
FF has a Quick ratio (1.07) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.67 | ||
| Quick Ratio | 1.07 |
3. Growth
3.1 Past
FF shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 147.03%, which is quite impressive.
FF shows a small growth in Revenue. In the last year, the Revenue has grown by 1.78%.
The Revenue has been growing by 8.83% on average over the past years. This is quite good.
EPS 1Y (TTM)147.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.62%
Revenue 1Y (TTM)1.78%
Revenue growth 3Y7.75%
Revenue growth 5Y8.83%
Sales Q2Q%12.18%
3.2 Future
Based on estimates for the next years, FF will show a very strong growth in Earnings Per Share. The EPS will grow by 27.39% on average per year.
FF is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.10% yearly.
EPS Next Y53.89%
EPS Next 2Y36.38%
EPS Next 3Y29.85%
EPS Next 5Y27.39%
Revenue Next Year5.61%
Revenue Next 2Y9.55%
Revenue Next 3Y9.52%
Revenue Next 5Y12.1%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 10.81, the valuation of FF can be described as reasonable.
Compared to the rest of the industry, the Price/Earnings ratio of FF indicates a rather cheap valuation: FF is cheaper than 95.45% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 27.25. FF is valued rather cheaply when compared to this.
FF is valuated correctly with a Price/Forward Earnings ratio of 13.70.
Based on the Price/Forward Earnings ratio, FF is valued cheaper than 95.45% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of FF to the average of the S&P500 Index (23.98), we can say FF is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.81 | ||
| Fwd PE | 13.7 |
4.2 Price Multiples
100.00% of the companies in the same industry are more expensive than FF, based on the Enterprise Value to EBITDA ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 5.87 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of FF may justify a higher PE ratio.
A more expensive valuation may be justified as FF's earnings are expected to grow with 29.85% in the coming years.
PEG (NY)0.2
PEG (5Y)N/A
EPS Next 2Y36.38%
EPS Next 3Y29.85%
5. Dividend
5.1 Amount
FF has a Yearly Dividend Yield of 1.50%. Purely for dividend investing, there may be better candidates out there.
Compared to an average industry Dividend Yield of 0.54, FF pays a better dividend. On top of this FF pays more dividend than 95.45% of the companies listed in the same industry.
FF's Dividend Yield is slightly below the S&P500 average, which is at 1.92.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.5% |
5.2 History
The dividend of FF has a limited annual growth rate of 4.24%.
Dividend Growth(5Y)4.24%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
FF pays out 18.40% of its income as dividend. This is a sustainable payout ratio.
The dividend of FF is growing, but earnings are growing more, so the dividend growth is sustainable.
DP18.4%
EPS Next 2Y36.38%
EPS Next 3Y29.85%
BIT:FF (1/13/2026, 10:06:06 AM)
9.62
+0.08 (+0.84%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners12%
Inst Owner ChangeN/A
Ins Owners53.17%
Ins Owner ChangeN/A
Market Cap212.22M
Revenue(TTM)373.66M
Net Income(TTM)18.62M
Analysts85.45
Price Target12.51 (30.04%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.5% |
Yearly Dividend0.12
Dividend Growth(5Y)4.24%
DP18.4%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.66%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)13.48%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.07%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.81 | ||
| Fwd PE | 13.7 | ||
| P/S | 0.58 | ||
| P/FCF | N/A | ||
| P/OCF | 5.75 | ||
| P/B | 1.55 | ||
| P/tB | 1.71 | ||
| EV/EBITDA | 5.87 |
EPS(TTM)0.89
EY9.25%
EPS(NY)0.7
Fwd EY7.3%
FCF(TTM)-0.21
FCFYN/A
OCF(TTM)1.67
OCFY17.39%
SpS16.64
BVpS6.22
TBVpS5.62
PEG (NY)0.2
PEG (5Y)N/A
Graham Number11.16
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.89% | ||
| ROE | 13.58% | ||
| ROCE | 14.28% | ||
| ROIC | 9.84% | ||
| ROICexc | 11.04% | ||
| ROICexgc | 11.92% | ||
| OM | 7.85% | ||
| PM (TTM) | 5.07% | ||
| GM | 34.77% | ||
| FCFM | N/A |
ROA(3y)-0.42%
ROA(5y)0.94%
ROE(3y)-1.24%
ROE(5y)0.96%
ROIC(3y)3.16%
ROIC(5y)3.16%
ROICexc(3y)3.64%
ROICexc(5y)4.57%
ROICexgc(3y)4.02%
ROICexgc(5y)5.02%
ROCE(3y)4.59%
ROCE(5y)4.62%
ROICexgc growth 3Y13.05%
ROICexgc growth 5Y-1.19%
ROICexc growth 3Y17.44%
ROICexc growth 5Y-2.63%
OM growth 3Y24.97%
OM growth 5Y2.12%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.32%
GM growth 5Y2.27%
F-Score7
Asset Turnover1.36
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.44 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 1.35 | ||
| Cap/Depr | 262.56% | ||
| Cap/Sales | 11.33% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 82.61% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.67 | ||
| Quick Ratio | 1.07 | ||
| Altman-Z | 3.06 |
F-Score7
WACC9%
ROIC/WACC1.09
Cap/Depr(3y)145.26%
Cap/Depr(5y)138.08%
Cap/Sales(3y)9.82%
Cap/Sales(5y)9.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)147.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.62%
EPS Next Y53.89%
EPS Next 2Y36.38%
EPS Next 3Y29.85%
EPS Next 5Y27.39%
Revenue 1Y (TTM)1.78%
Revenue growth 3Y7.75%
Revenue growth 5Y8.83%
Sales Q2Q%12.18%
Revenue Next Year5.61%
Revenue Next 2Y9.55%
Revenue Next 3Y9.52%
Revenue Next 5Y12.1%
EBIT growth 1Y70.93%
EBIT growth 3Y34.65%
EBIT growth 5Y11.14%
EBIT Next Year142.69%
EBIT Next 3Y46.91%
EBIT Next 5Y31.96%
FCF growth 1Y57.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y568.5%
OCF growth 3YN/A
OCF growth 5Y19.07%
FINE FOODS & PHARMACEUTICALS / FF.MI FAQ
What is the fundamental rating for FF stock?
ChartMill assigns a fundamental rating of 6 / 10 to FF.MI.
Can you provide the valuation status for FINE FOODS & PHARMACEUTICALS?
ChartMill assigns a valuation rating of 7 / 10 to FINE FOODS & PHARMACEUTICALS (FF.MI). This can be considered as Undervalued.
Can you provide the profitability details for FINE FOODS & PHARMACEUTICALS?
FINE FOODS & PHARMACEUTICALS (FF.MI) has a profitability rating of 6 / 10.
Can you provide the financial health for FF stock?
The financial health rating of FINE FOODS & PHARMACEUTICALS (FF.MI) is 5 / 10.
Can you provide the expected EPS growth for FF stock?
The Earnings per Share (EPS) of FINE FOODS & PHARMACEUTICALS (FF.MI) is expected to grow by 53.89% in the next year.